The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma
Navin Pinto(Seattle Children's Hospital), Julie R. Park(Seattle Children's Hospital), Joshua A. Gustafson(Seattle Children's Hospital), Ashley Wilson(Center for Infectious Disease Research), Nicholas A. Vitanza(Seattle Children's Hospital), Catherine M. Albert(Seattle Children's Hospital), Stephanie Rawlings-Rhea(Seattle Children's Hospital), Christopher Brown, Wenjun Huang(Lishui Central Hospital), Bonnie Cole(Howard Hughes Medical Institute), Cecilia C.S. Yeung(University of Washington), Jason Wendler(Pacific Northwest National Laboratory), Rebecca Gardner(Seattle Children's Hospital), Stephanie Mgebroff(Bloodworks Northwest), Kristy Seidel(Fred Hutch Cancer Center), Mallory Taylor(Center for Cancer and Blood Disorders), Adam Beebe, Heidi B. Ullom(Seattle Children's Hospital), Michael C. Jensen(Seattle Children's Hospital), Jocelyn H. Wright(Fred Hutch Cancer Center), Annette Künkele(Humboldt-Universität zu Berlin)
Cited by 0
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
|Blood|2017|1.1k
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
|Clinical Cancer Research|2015|754